/ /

  • linkedin
  • Increase Font
  • Sharebar

    Innovation in glaucoma thriving

    advances in pharmaceuticals, devices, and diagnostics fueling growth for sector

     

    Ono Pharma USA

    Ono has a long history of work with prostaglandin ligands, a history that is fueling development of a novel FP/EP-3 dual receptor agonist to treat glaucoma. Data from a 25-day clinical trial in ocular hypertension and open angle glaucoma suggest that the company is on track to produce its first-ever glaucoma drug.

    “Our preclinical studies showed significant and profound IOP lowering that was greater than latanoprost alone or in combinations with other agents,” said Andrew Wood, PhD, global clinical director. “The phase I safety and tolerability studies that compared three doses against placebo gave very similar data.”

    The trial used three doses, 3, 10, 20, and 30 μg/mL as a single dose followed by 14 days of daily dosing. After 14 days of dosing, the 10 μg/mL and 30 μg/mL doses showed a 35% IOP lowering. Latanoprost, based on historical data, provides a 26.8% to 34.4% reduction in IOP over a similar period. IOP lowering was sustained up to 33 hours after the last dose.

    “The duration of IOP lowering strongly suggests that this might be a once-a-day dosing drug,” Dr. Wood said. “These results suggest the need for additional phase II trials to compare safety and efficacy to other IOP lowering agents, particularly the prostaglandins.”

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results